

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete If Known

Application Number	09/875,076	10/782,596
Filing Date	June 6, 2001	02/19/2004
First Named Inventor	C. Liaw et al.	
Art Unit	1646	
Examiner Name	Premia Maria Merte	Ruixiang Li
Attorney Docket Number	AREN-11.US9.DIV (0239)	

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Ruixiang Li

Date Considered

3/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	09/875,076 1d782,596
Filing Date	June 6, 2001 02/19/2004
First Named Inventor	C. Liaw et al.
Group Art Unit	1646
Examiner Name	Prerna Maria Mertz RuiXiang Li
Attorney Docket Number	AREN-11.US9.DIV (0239)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Hirsch et al., "Neuronal Vulnerability in Parkinson's Disease", <i>J Neural Transm Suppl.</i> 1997;50:79-88	
		Hudley et al., "Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons <i>In Vivo</i> ", <i>European Journal of Neuroscience</i> , Vol. 7, pp. 2431-2440, 1995	
		Berridge, Michael J., "Inositol trisphosphate and calcium signalling", <i>Nature</i> , Vol. 361, 28 January 1993	
		Wilson et al., "Orphan G-Protein-coupled receptors: the next generation of drug targets?", <i>British Journal of Pharmacology</i> (1998) 125, 1387-1392	
		Hegyi et al., "The Relationship between Protein Structure and Function: a Comprehensive Survey with Application to the Yeast Genome", <i>J. Mol. Biol.</i> (1999) 288, 147-164	
RLi		Kasuya et al., "Three-dimensional Structure Analysis of PROSITE Patterns", <i>J. Mol. Biol.</i> (1999) 288, 1673-1691	

Examiner
Signature

RuiXiang Li

Date
Considered

3/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	09/875,076	10/12, 596
Filing Date	June 6, 2001	02/19/2011
First Named Inventor	Chen Liaw	
Group Art Unit	1646	
Examiner Name	P. Mertz	RuiXiang Li
Attorney Docket Number	11.US9.DIV (AREN-0239)	

[illegible][illegible]

3 | 21 | 2006

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/875,076 16/782,596
Filing Date	June 6, 2001 02/19/2004
First Named Inventor	Chen Liaw
Group Art Unit	1646
Examiner Name	P. Mertz Ruixiang Li
Attorney Docket Number	11.US9.DIV (AREN-0239)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	BA	Standaert and Young, Treatment of Central Nervous System Degenerative Disorders, in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, Ninth Ed. (Chapter 22) pp. 503-519, 1998	
RLi	BB	Matsumoto, et al., "An Evolutionarily Conserved G-Protein Coupled receptor Family, SREB, Expressed in the Central Nervous System," Biochem. Biophys. Res. Comm. (2000) 272:578-582	
RLi	BC	Skotnick, et al., "Structural genomics and its importance for gene function analysis," Nature Biotechnol. (2000) 18:283-287	

Examiner
Signature

Ruixiang Li

Date
Considered

3/21/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076
		Applicant Ruoping Chen, et al. Liaow	
		Filing Date ^{02/19/2004} June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	AA	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , 1996, 271, 1748-1755	
	AB	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK ₂) receptors," <i>Am. Rev. Respir. Dis.</i> , 1992, 146(5, Pt. 1), 1177-1181	
	AC	Alexander, W.S. et al., "Point mutations within the dimer interact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578	
	AD	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349	
	AE	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine _{2C} receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , 1994, 269(16), 11687-11690	
	AF	Baxter, G., "5-HT ₂ receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , 1995, 16, 105-110	
	AG	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family," <i>Nature</i> , 1986, 320, 415	
	AH	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G _{q/11} by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , 1995, 270, 17741-17748	
✓	AI	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, 1998, 363-377	
RLi	AJ	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the α-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925	
EXAMINER		<i>Ruixiang L</i>	DATE CONSIDERED 3/21/2006

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 101783,596 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Ruoping Chen, et al. Liauw	
		Filing Date 07/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	AK	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , 1996, 51(4), 539-544	
	AL	Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," <i>J. Biol. Chem.</i> , 1996, 271(6), 2882-2885	
	AM	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G _q ," <i>FEBS Lett.</i> , 1995, 363(3), 261-263	
	AN	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , 1994, 46, 121-136	
	AO	Casey, C. et al., "Constitutively active mutant 5-HT _{2A} serotonin receptors: inverse agonist activity of classical 5HT _{2A} antagonists," <i>Soc. Neurosci.</i> , 1996, Abstract #699.10	
	AP	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 7336-7340	
	AQ	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," <i>J. Biol. Chem.</i> , 1995, 270, 23398-23401	
	AR	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , 1993, 46(1), 131-134	
	AS	Chen, W. et al., "A colorimetric assay for measuring activation of G _s - and G _q -coupled signaling pathways," <i>Anal. Biochem.</i> , 1995, 226(2), 349-354	
	AT	Chidiac, P. et al., "Inverse agonist activity of β -adrenergic antagonists," <i>J. Pharm. Exp. Ther.</i> , 1994, 45, 490-499	
RLi	AU	Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," <i>J. Cardiovas. Pharmacol.</i> , 1993, 22(Suppl. 8), S377-S379	
EXAMINER		Ruoping Chen	DATE CONSIDERED 3/21/2006

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 10/782,596
		Applicant Ruoping Chen, et al. Law	
		Filing Date 02/11/2001 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	AV	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , 1996, 16(2), 5518-5526	
	AW	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , 1984, 311, 29-33	
	AX	De Dios, I. et al., "Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , 1994, 9(2), 212-218	
	AY	Desbios-Mouthon, C. et al., "Deletion of Asn ²⁸¹ in the α -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , 1996, 81(2), 719-727	
	AZ	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , 1991, 6(11), 1997-2003	
	BA	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , 1992, 7, 2549-2553	
	BB	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , 1994, 7, 396-401	
	BC	Eggericksx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , 1995, 309, 837-843	
	BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , 1992, 35, 3919-3927	
	BE	Fu, M. et al., "Functional autoimmune epitope on α_1 -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , 1994, 344, 1660-1663	
	BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene <i>c-kit</i> in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of <i>c-kit</i> Product," <i>J. Clin. Invest.</i> , 1993, 92, 1736-1744	
RLi	BG	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), 200-206	
EXAMINER <i>Ruoping Chen</i>		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 ^{10/782,596}
		Applicant Ruoping Chen, et al. Lian	
		Filing Date ^{02/19/2004} June 6, 2001	Group ¹⁶⁴⁶ Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	BH	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , 1995, 275(2), 737-744	
	BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , 1996, 87(5), 1692-1697	
	BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , 1995, 11(1), 76-82	
	BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , 1996, 271(4), 1857-1860	
	BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , 1984, 74, 647-651	
	BM	Herrick-Davis, K. et al., "Constitutively Active 5HT _{2C} Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18	
	BN	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , 1995, 47, 267-270	
	BO	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , 1990, 42(1), 45-83	
	BP	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , 1995, 270(13), 7405-7410	
↓	BQ	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , 1991, 78(11), 2962-2968	
RLi	BR	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , 1992, 42, 982-990	
EXAMINER <i>Ruoping Chen</i>		DATE CONSIDERED <i>3/21/2006</i>	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 10/782,596
		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/19/2001 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	BS	Jakubik, J. et al., "Constitutive activity of the M ₁ -M ₄ subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," <i>FEBS Letts.</i> , 1995, 377, 275-279	
	BT	Kjelsberg, M.A. et al., "Constitutive activation of the α_{1B} -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biol. Chem.</i> , 1992, 267(3), 1430-1433	
	BU	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , 1995, 9, 516-525	
	BV	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , 1995, 4(2), 183-188	
	BW	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , 1993, 7, 114-130	
	BX	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the <i>erbB</i> -3 tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2900-2904	
	BY	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," <i>J. Pharm. Exp. Therap.</i> , 1996, 277(2), 840-851	
	BZ	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene <i>c-kit</i> Product," <i>Blood</i> , 1991, 78(11), 2834-2840	
Y	CA	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , 1994, 271(1), 267-276	
RLi	CB	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," <i>J. Clin. Endocrinol. Metabl.</i> , 1995, 80(8), 2490-2494	
EXAMINER Ruoping Lu		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 15782,596
		Applicant Ruoping Chen, et al. Liao	
		Filing Date 02/19/2004 June 6, 2001	Group 1846 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	CC	Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , 1995, 92, 1906-1910	
	CD	Løvlie, R. et al., "The Ca ²⁺ -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet.</i> , 1996, 98, 129-133	
	CE	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , 1993, 14, 300-307	
	CF	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , 1985, 313, 144-147	
	CG	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," <i>Oncogene</i> , 1992, 7, 181-185	
	CH	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , 1996, 271(11), 6172-6178	
	CI	Lonardo, F. et al., "The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , 1990, 2(11), 992-1003	
	CJ	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , 1990, 173(3), 1169-1178	
	CK	Mann, J. et al., "Increased serotonin, and β -adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , 1986, 43, 954-959	
	CL	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8	
RLi	CM	Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," <i>Circulation</i> , 1994, 89, 2760-2767	
EXAMINER		Rui Liang L.	DATE CONSIDERED 3/21/2006

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 09/875,076-10/782,596
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Ruoping Chen, et al. Liao	
		Filing Date 02/19/2001 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	CN	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047	
	CO	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854	
	CP	Nanevich, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , 1996, 271(2), 702-706	
	CQ	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-750	
	CR	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , 1995, 270(44), 26037-26040	
	CS	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , 1992, 263(1), 241-245	
	CT	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β_2 -adrenergic receptor," <i>J. Biol. Chem.</i> , 1988, 263(31), 15985-15992	
	CU	Offermanns, S. et al., " $G_{\alpha_{15}}$ and $G_{\alpha_{16}}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , 1995, 270, 15175-15180	
	CV	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , 1994, 37, 4508-4521	
	CW	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , 1996, 271(14), 7949-7955	
RLi	CX	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metab.</i> , 1996, 81, 3584-3588	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 10/782, 596
		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651	
	CZ	Pei, G. et al., "A constitutive active mutant β_2 -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702	
	DA	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354	
	DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , 1995, 4 (Suppl. 1), 18-28	
	DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , 1993, 45, 289-293	
	DD	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , 1991, 49, 323-328	
	DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429	
	DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and ^3H -acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , 1993, 25(5), 271-276	
	DG	Ren, Q. et al., "Constitutive active mutants of the α_2 -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268, 16483-16487	
	DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active ET_A receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417	
	DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , 1993, 72, 827-834	
RLi	DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , 1993, 53(22), 5355-5360	
EXAMINER Rui Liang L-		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 09/875,076 14782,586
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/19/2004 June 6, 2001	Group 1146 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	DK	Samama, P. et al., "A mutation-induced activation state of the β 2-adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268(7), 4625-4636	
	DL	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," <i>Am. Soc. Pharm. Exp. Ther.</i> , 1996, 50, 285-292	
	DM	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73, 805-811	
	DN	Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Rec. Signal Transduct. Res.</i> , 1997, 17(1-3), 57-73	
	DO	Scheer, A. et al., "The activation process of the α_{1B} -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 808-813	
	DP	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human α -1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," <i>J. Pharmacol.</i> , 1995, 272(1), 134-142	
	DQ	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5699-5703	
	DR	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , 1994, 15, 264-270	
	DS	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , 1993, 365, 441-445	
	DT	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V_{1a} receptors," <i>J. Clin. Invest.</i> , 1993, 92, 224-231	
RLi	DU	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," <i>Mol. Cell. Endocrinology</i> , 1994, 100, 115-119	
EXAMINER		Ruixiang Li	DATE CONSIDERED 3/24/2006

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 — 10/82,596
		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/15/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	DV	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , 1992, 80(12), 3070-3078	
	DW	Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," <i>Anal. Biochem.</i> , 1994, 223, 259-265	
	DX	Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene," <i>Science</i> , 1987, 235, 177-182	
	DY	Slamon, D. et al., "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," <i>Science</i> , 1989, 244, 707-712	
	DZ	Solomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , 1974, 58, 541-548	
	EA	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," <i>Ann. Rev. Physiol.</i> , 1995, 58, 143-170	
	EB	ter Laak, A. et al., "Modelling and mutation studies on the histamine H ₁ -receptor agonist binding site reveal different binding modes for H ₁ -agonists: Asp ¹¹⁶ (TM3) has a constitutive role in receptor stimulation," <i>J. Computer-Aided Mol. Design</i> , 1995, 9, 319-330	
	EC	Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," <i>J. Biol. Chem.</i> , 1994, 269(45), 27925-27931	
	ED	Tsujimura, T. et al., "Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," <i>Blood</i> , 1996, 87(1), 273-283	
Y	EE	Wang, Z. et al., "Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," <i>Life Sci.</i> , 1994, 54(20), 339-350	
RLi	EF	Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," <i>Proc. Natl. Acad. Sci USA</i> , 1992, 89, 2140-2144	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 10/782, 596 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/19/2004 June 6, 2001—	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	EG	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , 1996, 88(3), 809-816	
	EH	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , 1996, 15, 520-527	
	EI	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312	
	EJ	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas <i>in vitro</i> ," <i>J. Biol. Chem.</i> , 1992, 267(18), 12452-12461	
	EK	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , 1995, 270, 22772-22778	
	EL	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor (<i>Met</i>)," <i>Oncogene</i> , 1994, 9, 1691-1697	
	EM	Pauwels P.J. et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Neurobiology</i> , 1998, 17, pp. 109-135.	
	EN	Shryock, John et al., "Inverse Agonists and Neutral Antagonists of Recombinant Human A ₁ Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells," <i>Molecular Pharmacology</i> , 1998, 53, pp. 886-893.	
	EO	Wenzel-Seifert et al., "High Constitutive Activity of the Human Formyl Peptide Receptor", <i>Journal of Biological Chem.</i> , 1998, 273, pp. 24181-24189.	
V	EP	Forman, B.M., et al., "Androstane Metabolites Bind to and Deactivate the Nuclear Receptor CAR- β ", <i>Nature</i> , 1998, 395, pp. 612-615.	
RLi	EQ	Seifert R. et al., "Different Effects of G α Splice Variants on β_2 -Adrenoreceptor-mediated Signaling, <i>Journal of Biological Chem.</i> , 1998, 273, pp. 5109-5116.	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 10782, 596 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Ruoping Chen, et al. hian	
		Filing Date 02/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	ER	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. & Biophys. Res. Comm.</i> , 1992, XP-002145165, 183(3), 989-995	
	ES	Gantz, I., et al., "Molecular cloning, expression, and gene localization of a fourth melanocortin receptor," <i>J. Biol. Chem.</i> , 1993, XP-002051983, 268(20), 15174-15178	
	ET	Grobowski, T., et al., "Mutation of Asn ¹¹¹ in the third transmembrane domain of the AT _{1a} angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , 1997, XP-002145162, 272(3), 1822-1826	
	EU	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , 1994, XP-002145166, 203(3), 1842-1850	
	EV	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , 1998, XP000929737, 17(6), 493-500	
	EW	Noda, K., et al., "The active state of the AT ₁ angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , 1996, XP-002145163, 35, 16435-16442	
	EX	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , 1996, XP-002145161, 219-2254	
	EY	Scheer, A., et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Receptor & Signal Transduction Res.</i> , 1997, XP-000867531, 17(1-3), 57-73	
	EZ	Munzy D. et al., "Homo sapeins chormosome 2p13.3, clone RPCI111-433J6 - sequencing in progress - 100 unordered pieces." <i>EMBL Database Accession Number AC006087</i> , 1998.	
RLi	FA	Smith D.R., "Sequencing of human chromosome 10", <i>EMBL Database Accession Number AC005849</i> , 1998.	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 101782, 596 09/875,076
		Applicant Ruoping Chen, et al. Liaw	
		Filing Date 02/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	FB	O'Dowd B.F. et al., "Discovery of Three Novel G-Protein-Coupled Receptor Genes", <i>Genomics</i> , 1998, 47, pp. 310-313. (Whole document)	
	FC	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AI090920</i> , 1998. (Abstract)	
	FD	Matsuoka I. et al., "Identification of Novel members of G-protein coupled receptor subfamily", <i>Biochemical and Biophysical Research Communications</i> , 1993, 194. (whole document)	
	FE	Hillier L. et al., "Generation and analysis of 280000 human expressed sequence tags", <i>EMBL Database Accession Number H67224</i> , 1995, abstract.	
	FF	Strausberg R., "National Cancer Institute, Cancer Genome Project", <i>EMBL Database Accession Number AI131555</i> , 1998, abstract.	
	FG	Weng et al., "A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M", <i>Proceedings of the National Acad. Of Sciences of USA</i> , 1998, 95, whole document.	
	FH	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AA804531</i> , 1998, abstract.	
	FI	Stadel, et al., "Orphan G Protein-Coupled Receptors: A neglected opportunity for pioneer drug discovery", <i>Trends in Pharm. Sciences</i> , 1997, 18, pp. 430-437.	
	FJ	Williams, S., "Human DNA Sequence From close 417022 on Chromosome 6q16.1-16.3.", <i>EMBL Database Entry HS417022</i> , 1998, pp. 1-34.	
*	FK	Nichols, J.G. et al. (eds), "Indirect mechanisms of synaptic transmission", <i>From Neuron to Brain</i> , 3 rd edition, Sinauer Associates, Inc., 1992	
*	FL	Oslo et al. (Eds), <i>Remington's Pharmaceutical Sciences</i> , 16 th edition, Mack Publishing Co., 1980	
EXAMINER Ruoxiang Li		DATE CONSIDERED 3/21/2006	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AREN-0239	Serial No. 09/875,076 10/782,596
		Applicant Ruoping Chen, et al. Liao	
		Filing Date 02/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	FM	Gantz, I. et al., "Molecular cloning of a novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 268(11), pp 8246-8250	
	FN	Howard, A.D. et al., "A receptor in pituitary and hypothalamus that functions in growth hormone release", <i>Science</i> , 1996, 273, pp 974-977	
	FO	Iismaa, T.P. et al., "Isolation and chromosomal localization of a novel human G-protein-coupled receptor (GPR3) expressed predominately in the central nervous system", <i>Genomics</i> , 1994, 24, pp391-394	
	FP	Heiber, M. et al., "Isolation of three novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 26(11), pp 8246-8250	
	FQ	Bertin, B. et al., "Cellular signaling by an agonist-activated receptor/Gs-alpha fusion protein", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, pp 8827-8831	
	FR	Wise, A. et al., "Rescue of functional interactions between the alpha-2-A-adrenoreceptor and acylation-resistant forms of Gil-alpha by expressing the proteins from chimeric open reading frames", <i>J. Biol. Chem.</i> , 1997, 272, pp 24673-24678	
	FS	Burt, A.R., et al. "Agonist occupation of an alpha-2-A-adrenoreceptor-Gil-alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins", <i>J. Biol. Chem.</i> , 1997, 272, pp 10367-10375	
	FT	Jensen et al., "mRNA profiling of rat islet tumors reveals Nkx 6.1 as a Cell-specific homeodomain transcription factor", <i>J. Biol. Chem.</i> , 1996, 271(31), pp 18749-18758	
	FU	Konig et al., "Method for identifying ligands that bind to cloned Gs-orGi-coupled receptors", <i>Mol. Cell. Neuro.</i> , 1991, 2, pp331-337	
	FV	Leonard, J. et al., "The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells", <i>Proc Natl. Acad. Sci. USA</i> , 1992, 89, pp 6247-6251	
	FW	Marchese, A. et al., "Cloning of human genes encoding novel G protein-coupled receptors", <i>Genomics</i> , 1994, 23, pp 609-618	
RLi	FX	Marks, D.L. et al., "Simultaneous visualization of two cellular mRNA species in individual neurons by use of a new double in situ hybridization method", <i>Mol. & Cell. Neuro.</i> , 1992, 3, pp 395-405	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/21/2006	

Form PTO-1449 Modified		Docket No. AREN-0239	Serial No. 10/782,596 -09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Ruoping Chen, et al. Lian	
		Filing Date 02/19/2004 June 6, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	FY	O'Dowd, B. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes", <i>Gene</i> , 1997, 187, pp75-81	
	FZ	Sakuri, T. et al., "Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", <i>Cell</i> , 1998, 92, pp 573-585	
	GA	Song, Z.H., et al. "Molecular cloning and chromosomal localization of human genes encoding three closely related G-protein-coupled receptors", <i>Genomics</i> , 1995, 28, pp 347-349	
	GB	Suzuki, M. et al., "Regulatable promoters for use in gene therapy applications: Modification of the 5'-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low level gene expression that can be upregulated by exogenous agents that raise intracellular levels of cAMP", <i>Human Gene Therapy</i> , 1996, 7, pp 1883-1893	
	GC	Xu, Y. et al., "Identification of human OGR1, a novel G Protein-coupled receptor that maps to chromosome 14", <i>Genomics</i> , 1996, 35, pp 397-402	
	GD	Gellai, M. et al., "Nonpeptide endothelin receptor antagonists V: prevention and reversal of acute renal failure in the rat by SB 209670", <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), pp 200-206	
	GE	Heiber, M. et al., "Isolation of three novel human genes encoding G protein-coupled receptors", <i>DNA and Cell Biology</i> , 1995, 14(1), pp 25-35	
	GF	Itoh, H. et al., "Molecular cloning and sequence determination of cDNAs for subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain", <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, pp 3776-3780	
y	GG	Kenakin, T., "Are receptors promiscuous? Intrinsic efficacy as a transduction phenomenon", <i>Life Sciences</i> , 1998, 43, pp 1095-1101	
RLi	GH	Martone, R.L. et al. "Human CRF receptor chimeras: Mapping of ligand binding determinants", 26 th meeting of the society of Neuroscience, Washington, D.C., November 16-21, 1996, Abstract No. 609.8	
EXAMINER Ruixiang Li		DATE CONSIDERED 3/1/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. AREN-0239		Serial No. 09/875,076 14782,596	
				Applicant Ruoping Chen, et al. Liao			
				Filing Date 02/19/2004 June 6, 2001		Group 1646 Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
RLi	GI	5,514,578	05/07/96	Hogness et al.	435	240.2	
	GJ	5,532,157	07/02/96	Fink	435	240.2	
	GK	5,573,944	11/12/96	Kirschner et al.	435	252.3	
↓	GL	5,639,616	06/17/97	Liao et al.	435	7.1	
RLi	GM	5,750,353	05/12/98	Kopin et al.	435	7.21	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GN	WO 97/11159	09/20/96	PCT	X		
	GO	WO 98/46995	10/22/98	PCT	X		
	GP	WO 99/52927	10/21/99	PCT	X		
↓	GQ	WO 98/00552	01/08/98	PCT	X		
RLi	GR	WO 98/34948	08/13/98	PCT	X		
EXAMINER Ruoxiang Li				DATE CONSIDERED 3/21/2006			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. AREN-0239		Serial No. 09/875,076 10/282,596	
				Applicant Ruoping Chen, et al. Lian			
				Filing Date 02/15/2001 June 6, 2001		Group 1646 Not Yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GS	2,135,523 CA	08/05/96	Canada	X		
↓	GT	WO 99 24569	05/20/99	Japan	X(abstract only)		
↓	GU	WO 97 21731 A	06/19/97	PCT	X		
RLi	GV	WO 98 38217 A	09/03/98	PCT	X		
EXAMINER Ruixiang Li				DATE CONSIDERED 3/21/2006			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. AREN-0239		Serial No. <u>101782, 596</u> 09/875,076	
				Applicant Ruoping Chen, et al. <i>Lian</i>			
				Filing Date <u>02/19/2004</u> June 6, 2001		Group <u>1646</u> Not Yet Assigned	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GW	WO 00 23588	04/27/00	PCT	X		
	GX	WO 99 55732	04/11/99	PCT	X		
	GY	WO 99 46378	09/16/99	Japan	X(abstract)		
	GZ	WO 98 39441	09/11/98	PCT	X		
	HA	WO 99 24463	05/20/99	PCT	X		
	HB	EP 0 899 332	03/03/99	EPO	X		
	HC	WO 00 26369	05/11/00	PCT	X		
	HD	WO 99 52946	10/21/99	PCT	X		
	HE	WO 98 31810	07/23/98	PCT	X		
	HF	EP 0 860 502	08/26/98	EPO	X		
	HG	WO 99 25830	05/27/99	PCT	X		
	HH	WO 99 55734	11/04/99	PCT	X		
RLi	HI	WO 00 12707	03/09/00	PCT	X		
EXAMINER <i>Ruoxiang hi</i>				DATE CONSIDERED <u>3/21/2006</u>			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. AREN-0239		Serial No. 09/875,076 10/782, 596	
				Applicant Ruoping Chen, et al. Lian			
				Filing Date June 6, 2001		Group 1646 Not Yet Assigned	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Translation YES	NO	
RLi	HJ	WO 00 11170	03/02/00	PCT	X		
	HK	WO 00 11166	03/02/00	PCT	X		
	HL	WO 98 50549	11/12/98	PCT	X		
	HM	WO 00 28028	05/18/00	PCT	X		
	HN	WO 99 42484	08/26/99	PCT	X		
	HO	WO 97 20045	06/05/97	PCT	X		
	HP	WO 97 24929	07/17/97	PCT	X		
y	HQ	WO 00 11015	03/02/00	PCT	X		
RLi	HR	WO 98 46995	10/22/98	PCT	X		
EXAMINER Ruixiang Li				DATE CONSIDERED 3/24/2006			



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete If Known

Application Number	10/782,596
Filing Date	February 19, 2004
First Named Inventor	C.W. Liaw
Art Unit	Not Yet Assigned 1646
Examiner Name	Not Yet Assigned Ruixiang Li
Attorney Docket Number	11.US12.CON

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Examiner Signature	Ruxiang Li	Date Considered	3/21/2006
-----------------------	------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10782,596
Filing Date	02/19/2004
First Named Inventor	Liao et al.
Art Unit	1646
Examiner Name	Ruxiang Li
Attorney Docket Number	

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	A3	BENTLEY, "Genomic sequence information should be released immediately and freely to the public," The Sanger Institute, Human Genome Project Policy Forum, Science (1998) 274:533-534.	
	A4	The Sanger Institute: Data Release Policy, www.sanger.ac.uk, May 24, 2002.	
	A5	Genbank Acc. #AL035423, update version of February 12, 1999.	
	A6	Genbank Acc. #AL035423, update version of February 24, 1999.	
	A7	Genbank Acc. #AL035423, update version of February 27, 1999.	
	A8	Genbank Acc. #AL035423, update version of April 21, 1999.	
	A9	Genbank Acc. #AL035423, update version of November 23, 1999.	
RLi	A10	Sequence Revision History for Genbank Acc. #AL035423.	

Examiner
Signature

Ruxiang Li

Date
Considered

3/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

* Not in file



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

2

Complete if Known

Application Number	10/782,596
Filing Date	February 19, 2004
First Named Inventor	Chen Liaw
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	AREN11.US12.CON

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
RLi	A30	US-5,462,856	10-31-1995	Lerner et al.	
RLi	A31	US-6,051,386	04-18-2000	Lerner et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
Signature

Ruixiang Li


Date
Considered

3/21/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 (Rev. 12/2005)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/782,596
Filing Date	February 19, 2004
First Named Inventor	Chen Liaw
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	AREN11.US12.CON

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	A32	Gracheck et al., <i>Annual Rep. Med. Chem.</i> (1993) 28:161-166.	
	A33	Major et al. "Challenges of high throughput screening against cell surface receptors," <i>J. of Receptor and Signal Transduction Res.</i> (1995) 15:595-607.	
	A34	Jayawickreme et al. "Gene expression systems in the development of high-throughput screens," <i>Current Opinion in Biotechnology</i> (1997) 629-634.	
	A35	Ji et al., "G Protein-Coupled Receptors," <i>J. Biol. Chem.</i> (1998) 273:17299-17302.	
	A36	Smith et al., <i>Assays of Cycle Nucleotides: A Review of Current Techniques</i> , App. Biochem Biotechnol (1993) 41:189-218.	
RLi	A37	Murdoch et al., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> (2000) 95:3032-3043.	

Examiner Signature	Ruixiang Li	Date Considered	3/21/2006
-----------------------	-------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

References Cited

Application No. 09/187,076 Chen et al.
Examiner 10/20/06 Group Art Unit 1646
Page 1 of 1

U.S. PATENT DOCUMENTS

DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
B				
C				
D				
E				
F				
G				
H				
I				
J				
K				
L				
M				

FOREIGN PATENT DOCUMENTS

* DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N					
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

* DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U <u>Skolnick et al. Nature Biotechnology Vol. 18, pages 283-287</u>	<u>3/00</u>
V <u>Chen et al. PNAS USA Vol. 97, pages 2473-2477</u>	<u>1/00</u>
W <u>Skolnick et al., structural genomics and its importance for gene function analysis. Nature Biotechnology 18: 283-287, 2000.</u>	
X <u>Ruixiang Li</u>	<u>3/21/2006</u>

BEST AVAILABLE COPY

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)